WebDoctor Encyclopedia

GIST & neuroendocrine

Gastrointestinal neuroendocrine tumours

GI neuroendocrine tumours arise from gut neuroendocrine cells. This entry covers grade, somatostatin analogues, and peptide receptor radionuclide therapy.

Medically reviewed Last reviewed October 27, 2026

Overview

Gastrointestinal neuroendocrine tumours (GI-NETs) are a heterogeneous group of neoplasms arising from the diffuse neuroendocrine system cells scattered throughout the gastrointestinal tract. Previously referred to as “carcinoid tumours” (a term now largely reserved for well-differentiated NETs of the small bowel and appendix with specific clinical behaviour), modern classification emphasises histological grade, differentiation, and anatomical origin.

These tumours possess the unique ability to secrete bioactive amines and peptides (such as serotonin, histamine, tachykinins, and prostaglandins), leading to distinct clinical syndromes. While historically considered rare, the incidence of GI-NETs has risen significantly over the past three decades—largely due to improved endoscopic imaging, cross-sectional radiology, and pathological classification—making them the second most common gastrointestinal malignancy after colorectal adenocarcinoma in some epidemiological datasets.

Key Facts at a Glance

Feature Detail
Origin Neuroendocrine cells (Kulchitsky cells) of the GI mucosa
Most Common Sites Small intestine (ileum), Rectum, Appendix, Stomach, Colon
Peak Incidence 6th–7th decade of life (varies by primary site)
Gender Predilection Slight female predominance overall (varies by site)
Key Pathological Markers Chromogranin A, Synaptophysin, Ki-67 Index
Grading System WHO 2019 / ENETS: Grade 1 (Ki-67 <3%), Grade 2 (Ki-67 3–20%), Grade 3 (Ki-67 >20%)
Differentiation Well-differentiated (NET G1/G2/G3) vs. Poorly differentiated (NEC G3)

Aetiology and Risk Factors

The precise aetiology of sporadic GI-NETs remains incompletely understood. Unlike many epithelial cancers, strong environmental lifestyle links (e.g., smoking, alcohol) are less defined, though not absent.

Genetic Syndromes

Approximately 10–20% of GI-NETs occur in the context of hereditary syndromes. Recognition is critical for surveillance and family screening.

  • Multiple Endocrine Neoplasia Type 1 (MEN1): Autosomal dominant (MEN1 gene, chromosome 11q13). High penetrance for gastric (type 1), duodenal, and pancreatic NETs. Duodenal NETs in MEN1 are often multiple and associated with gastrinoma (Zollinger-Ellison syndrome).
  • Neurofibromatosis Type 1 (NF1): NF1 gene mutation. Strong association with periampullary/duodenal NETs (often somatostatinoma-like) and gastric NETs.
  • Von Hippel-Lindau (VHL) Disease: VHL gene mutation. Associated with pancreatic NETs (often non-functional) and, less commonly, small bowel NETs.
  • Tuberous Sclerosis Complex (TSC1/TSC2): mTOR pathway dysregulation. Associated with pancreatic and rectal NETs.
  • Succinate Dehydrogenase (SDH) Deficiency: SDHA, SDHB, SDHC, SDHD, SDHAF2 mutations. Characteristic for gastric NETs (Type 3-like) and paragangliomas/pheochromocytomas. Often younger onset, multifocal.

Sporadic Risk Factors

  • Chronic Atrophic Gastritis / Pernicious Anemia: Long-standing hypergastrinaemia drives enterochromaffin-like (ECL) cell hyperplasia → dysplasia → Type 1 Gastric NETs.
  • Proton Pump Inhibitor (PPI) Long-term Use: Induces hypergastrinaemia; debated link to sporadic gastric NETs, but established link to ECL hyperplasia.
  • Race/Ethnicity: Higher incidence of small bowel NETs in Black populations compared to White populations; rectal NETs more common in Asian populations.
  • Obesity & Metabolic Syndrome: Emerging epidemiological data suggests a link, particularly for colorectal NETs.

Classification Systems: The Language of Prognosis

Accurate classification dictates management. Three parallel systems are used clinically.

1. WHO Classification (2019) – Grading by Proliferation

This is the primary determinant of biological behaviour.

Grade Mitotic Count (per 2 mm² / 10 HPF) Ki-67 Index (%) Terminology
NET Grade 1 (G1) < 2 < 3% Well-differentiated NET
NET Grade 2 (G2) 2 – 20 3 – 20% Well-differentiated NET
NET Grade 3 (G3) > 20 > 20% Well-differentiated NET G3 (Distinct from NEC)
NEC Grade 3 (G3) > 20 > 20% Poorly differentiated Neuroendocrine Carcinoma (Small or Large cell)

Critical Distinction:** Well-differentiated NET G3 retains organoid morphology (nested/trabecular) and expresses high levels of somatostatin receptors (SSTR2). It behaves less aggressively than Poorly differentiated NEC G3, which requires platinum-based chemotherapy.

2. TNM Staging (AJCC 8th Edition / UICC) – Anatomical Extent

Site-specific staging exists for Stomach, Duodenum/Ampulla, Jejunum/Ileum, Appendix, Colon/Rectum. General principles:

  • T1: Invades submucosa (≤1 cm for most sites).
  • T2: Invades muscularis propria (>1 cm or size criteria).
  • T3: Invades subserosa or perirectal/pericolic fat.
  • T4: Invades adjacent organs/structures.
  • N1: Regional lymph node metastasis.
  • M1: Distant metastasis (M1a: liver only; M1b: extra-hepatic; M1c: both).

3. ENETS Staging (European Neuroendocrine Tumour Society)

Often preferred in Europe; provides more granular T-stage definitions for specific sites (e.g., distinguishing mesenteric invasion in small bowel NETs).

Anatomical Distribution and Site-Specific Biology

The clinical behaviour, secretory profile, and metastatic potential vary dramatically by primary site.

1. Small Intestine (Jejunum/Ileum) – The “Classic” Carcinoid

  • Epidemiology: Most common primary for metastatic NETs (ileum > jejunum).
  • Biology: Often multifocal (20–30%). High propensity for mesenteric fibrosis (desmoplastic reaction) causing bowel obstruction/ischaemia.
  • Secretory Profile: High serotonin (5-HT) production → Carcinoid Syndrome (flushing, diarrhoea, valvular heart disease) usually only with liver metastases (first-pass hepatic metabolism bypassed).
  • Genetics: Frequent CDKN2A/B loss, MEN1 mutations, Chr 18 loss.

2. Rectum

  • Epidemiology: Rising incidence (screening colonoscopy). Often small (<1 cm), G1.
  • Biology: Rarely secrete serotonin (lack aromatic amino acid decarboxylase). Non-functional clinically. Low metastatic potential if <1 cm, G1, no muscularis propria invasion.
  • Management: Endoscopic resection often curative for small lesions.

3. Stomach – Three Distinct Types

Type Background Mucosa Gastrin Level Behaviour Management
Type 1 Chronic Atrophic Gastritis / Autoimmune High (Hypergastrinaemia) Multiple, small (<1 cm), G1, Very low malignant potential (<5% metastasize) Endoscopic surveillance ± resection. Antrectomy reserved for large/multiple.
Type 2 MEN1 / Zollinger-Ellison High (Gastrinoma) Multiple, small, G1, Low malignant potential Treat gastrinoma (surgery/Somatostatin Analogues). Endoscopic resection for large lesions.
Type 3 Normal Mucosa (Sporadic) Normal Solitary, Large, G2/G3, High malignant potential (>50% metastatic at dx) Surgical resection (Gastrectomy + Lymphadenectomy).

4. Appendix

  • Incidental Finding: Often at appendectomy for appendicitis.
  • Goblet Cell Adenocarcinoma (GCA): Distinct entity (mixed neuroendocrine-non-neuroendocrine neoplasm – MiNEN). Behaves more aggressively (peritoneal spread). Requires right hemicolectomy if >2 cm or adverse features.

5. Colon

  • Rare. Often present at advanced stage (right colon). Behave similarly to adenocarcinoma but with NET histology. Treated with oncologic resection.

How Does It Look? (Pathology, Imaging & Endoscopic Appearance)

Understanding the visual phenotype of GI-NETs across diagnostic modalities is essential for recognition, staging, and treatment planning.

1. Gross Pathology & Macroscopic Appearance

  • Submucosal Nodules: The hallmark. Tumours arise deep to the muscularis mucosae. The overlying mucosa is often intact, smooth, and normal in colour (unlike adenocarcinoma which ulcerates early).
  • “Yellow-Tan” Colour: Cut surface typically reveals a firm, rubbery, yellow-tan tumour due to dense cellularity and vascularity.
  • Small Bowel “Classic” Appearance: Firm, puckering nodule in the ileum, often with radiating “spokes” of mesenteric fibrosis retracting the mesentery. This fibrosis encases mesenteric vessels and lymph nodes.
  • Appendiceal: Tip enlargement (mucocele-like) or diffuse infiltration. GCA shows mucinous appearance.
  • Rectal: Polypoid or sessile submucosal lesion, often <1–2 cm, yellowish.

2. Microscopic Histology (Light Microscopy)

  • Architecture: Organoid patterns: Nested (Zellballen), Trabecular, Glandular/Rosette, Insular, Solid sheets.
  • Cytology (Well-Differentiated): Uniform cells, “salt-and-pepper” chromatin (finely stippled), inconspicuous nucleoli, moderate amphophilic/eosinophilic cytoplasm. Low mitotic activity.
  • Cytology (Poorly Differentiated NEC): High N:C ratio, coarse chromatin, prominent nucleoli, necrosis, high mitotic rate (>20/10 HPF). Small cell vs. Large cell morphology.

3. Immunohistochemistry (IHC) – The Diagnostic Gold Standard

  • General Neuroendocrine Markers (Sensitivity >90%):
  • Synaptophysin: Vesicular protein; diffuse cytoplasmic staining. Most sensitive.
  • Chromogranin A (CgA): Dense core granule protein; granular cytoplasmic staining. Specificity high, but sensitivity lower in poorly differentiated/low granule tumours.
  • INSM1 (Insulinoma-Associated Protein 1): Nuclear stain. Highly sensitive and specific for neuroendocrine differentiation; superior to CgA in NEC and small biopsies.
  • Proliferation Marker:
  • Ki-67 (MIB-1): Nuclear staining. Mandatory for Grading. Counted in “hot spots” (2000 cells minimum).
  • Somatostatin Receptor 2A (SSTR2A): Membranous staining. Predicts response to Somatostatin Analogues (SSA) and Ga-68 DOTATATE PET avidity.
  • Site-Specific Markers:
  • CDX2: Nuclear. Positive in midgut (SI, Appendix, Right Colon) and hindgut (Rectum). Negative in Gastric (usually) and Pancreatic.
  • SATB2: Nuclear. Highly specific for Rectal/Colonic NETs (hindgut).
  • PAX6 / Islet Hormones (Insulin, Glucagon, Somatostatin): Pancreatic differentiation.
  • TP53 / Rb1 loss: Supports Poorly Differentiated NEC.

4. Endoscopic Appearance (White Light & Enhanced Imaging)

  • Submucosal Tumour (SMT) Lift Sign: When biopsied or injected, the lesion lifts poorly or shows a “cushion sign” (firm resistance).
  • Narrow Band Imaging (NBI) / Blue Light Imaging (BLI):
  • Rectal NETs: Often show fine, regular microvascular pattern (Type 2A vessels) or invisible vessels.
  • Gastric Type 1: Multiple tiny (<5mm) polypoids, often hyperemic.
  • Gastric Type 3: Large, solitary, often ulcerated (mimics adenocarcinoma).
  • Endoscopic Ultrasound (EUS):
  • Layer of Origin: 4th Layer (Muscularis Propria) or 3rd Layer (Submucosa).
  • Echogenicity: Typically hypoechoic, homogeneous.
  • Features of Malignancy/Deep Invasion: Irregular margins, heterogeneous echogenicity, disruption of the 5th layer (subserosa), suspicious lymph nodes (round, hypoechoic, distinct borders).

5. Cross-Sectional & Functional Imaging

Modality Appearance / Utility
Contrast-Enhanced CT / MRI Hypervascular enhancement (early arterial phase) due to dense capillary network. “Light bulb” brightness on arterial phase. Liver metastases are hypervascular. MRI (Liver-specific contrast) superior for hepatic lesion detection.
Ga-68 DOTATATE / DOTATOC / DOTANOC PET-CT Gold Standard Functional Imaging. High affinity for SSTR2. SUVmax correlates with grade (G1/G2 high uptake; G3 variable; NEC low/negative). Detects unknown primaries, occult nodal/metastatic disease. Guides PRRT eligibility.
FDG PET-CT Inverse correlation with differentiation. Low uptake in G1/G2 (indolent). High uptake in NET G3 and NEC (aggressive). Used for “flare” phenomenon prediction and grading discordance.
Octreoscan (SPECT/CT) Largely superseded by Ga-68 PET. Lower spatial resolution, whole body, 24h delay.

Symptoms: Clinical Presentation Syndromes

GI-NETs are chameleons. Presentation depends on tumour location, bulk, secretory activity, and presence of metastases.

1. Mechanical / Local Symptoms (Mass Effect)

  • Abdominal Pain: Vague, intermittent, colicky (small bowel). Chronic obstruction due to fibrosis.
  • Gastrointestinal Bleeding: Occult (iron deficiency anaemia) or overt (melena/hematochezia). Common in rectal NETs and ileal tumours (erosion of mucosa).
  • Obstruction: Small bowel obstruction (SBO) from intussusception (lead point), luminal narrowing, or mesenteric fibrosis kinking the bowel.
  • Appendicitis: Acute presentation for appendiceal NETs (obstruction of appendiceal lumen).
  • Rectal Symptoms: Tenesmus, change in caliber, sensation of incomplete evacuation (larger rectal NETs).

2. Functional Syndromes (Hormonal Hypersecretion)

These occur when bioactive substances reach systemic circulation in high concentrations. Liver metastases are usually required for midgut NETs (portal drainage → hepatic first-pass metabolism). Foregut (Gastric, Duodenal, Pancreatic) and Hindgut (Rectal) NETs drain systemically or via portal vein but often secrete different peptides.

A. Carcinoid Syndrome (Classic Midgut / Serotonergic)

Prevalence: ~10-20% of SI-NETs; requires liver mets (usually) or ovarian primary/retroperitoneal nodes draining via IVC.

  • Flushing (90%): Dry flushing (no sweating), violaceous/red, face/neck/upper trunk. Duration: seconds to 30 mins. Triggered by stress, alcohol, tyramine foods, anaesthesia.
  • Secretory Diarrhoea (80%): Watery, non-bloody, nocturnal, urgency. Due to serotonin (5-HT) increasing gut motility and secretion.
  • Carcinoid Heart Disease (Hedinger Syndrome) (20-50% of syndrome pts): Right-sided valvular fibrosis (Tricuspid regurgitation, Pulmonary stenosis). Left-sided disease rare unless PFO/ASD or very high bronchial NET serotonin. Caused by 5-HT + TGF-beta on valves.
  • Bronchospasm/Wheezing: Tachykinins/Prostaglandins.
  • Pellagra (Niacin Deficiency): Tryptophan diverted to serotonin → Niacin deficiency → Dermatitis, Dementia, Diarrhoea, Death.

B. Carcinoid Crisis (Life-Threatening Emergency)

  • Trigger: Anaesthesia induction, surgery, embolization, biopsy, stress.
  • Features: Profound hypotension (or hypertension), severe flushing, bronchospasm, arrhythmias, coagulopathy.
  • Prophylaxis/Treatment: IV Octreotide bolus (50–100 mcg) + infusion peri-procedurally. Avoid catecholamines (adrenaline) if possible (can paradoxically worsen via beta-receptor stimulation of tumour secretion).

C. Atypical Carcinoid Syndrome (Gastric NETs Type 1/2 / Foregut)

  • Patchy, intense, prolonged flushing (bright red, well-demarcated), often with lacrimation, salivation, periorbital oedema.
  • Mediated by Histamine and Kallikrein/Bradykinin (not just serotonin).
  • Bronchospasm more prominent.
  • Note: Gastric Type 3 NETs rarely cause syndrome.

D. Zollinger-Ellison Syndrome (Gastrinoma – Duodenal/Pancreatic NET)

  • Mechanism: Gastrin hypersecretion → massive acid output.
  • Symptoms: Refractory peptic ulcer disease (unusual locations: distal duodenum, jejunum), diarrhoea (acid inactivation of lipase + mucosal damage), GERD, weight loss.
  • Association: MEN1 (duodenal multiple small tumours).

E. Other Rare Functional Syndromes

  • VIPoma (Verner-Morrison Syndrome): Watery Diarrhoea, Hypokalaemia, Achlorhydria (WDHA). Pancreatic origin usually.
  • Glucagonoma: Necrolytic Migratory Erythema (rash), Diabetes, DVT, Weight loss.
  • Somatostatinoma: Diabetes, Steatorrhoea, Gallstones, Hypochlorhydria. Duodenal/Periampullary (NF1 association).
  • Insulinoma: Hypoglycaemia (Whipple’s triad). Pancreatic (technically Pan-NET, but relevant context).

F. Non-Functional / Silent Tumours

  • Majority of Rectal, Colon, Gastric Type 3, and many Pancreatic NETs.
  • Present with mass effect, weight loss, fatigue, or incidental findings.

3. Paraneoplastic & Systemic Features

  • Constitutional: Weight loss, fatigue, cachexia (advanced disease).
  • Neuromyopathic: Autoimmune associations (e.g., Anti-Hu, Anti-CV2) – rare, mostly with NEC.
  • Coagulopathy: Trousseau’s syndrome (migratory thrombophlebitis) – mucin/adenocarcinoma features or GCA.

Diagnostic Workup: A Stepwise Algorithm

1. Biochemical Markers (Blood/Urine)

Test Utility Notes
Chromogranin A (CgA) General tumour burden marker. Sensitivity 60-90% (varies by site). False +: PPI use (major), renal failure, heart failure, IBD, proton pump inhibitors. Stop PPI 2 weeks prior if possible.
Urinary 5-HIAA (5-Hydroxyindoleacetic Acid) Gold standard for Serotonin-secreting tumours (Carcinoid Syndrome). 24h urine collection. Dietary restrictions essential (avoid banana, pineapple, nuts, tomato, kiwi, avocado, plums, eggplant, walnuts 48h prior). Specificity >90%.
Fasting Serum Gastrin Diagnose ZES / Gastric NET typing. Must stop PPI ≥ 2 weeks (ideally 7-14 days). Secretin stimulation test if equivocal.
Pancreatic Polypeptide (PP), Neurokinin A (NKA) Adjunct markers; NKA correlates with tumour burden/prognosis in SI-NETs. Not universally available.
SDHB IHC / Genetic Testing If gastric NET, young age, multifocal, family history. Guides germline testing.

2. Endoscopy

  • Gastroscopy + Duodenoscopy (to D2/D3): Mandatory for Gastric NET typing (biopsies for histology + CgA/Synaptophysin + Gastrin level). Map number/size/location.
  • Colonoscopy: Full inspection. Rectal NETs: assess size, morphology, distance from anal verge (critical for surgery vs endoscopic resection).
  • Capsule Endoscopy / Device-Assisted Enteroscopy (Balloon/Spiral): For Small Bowel evaluation if cross-sectional imaging negative but biochemical/clinical suspicion high. Contraindicated if obstruction suspected.

3. Imaging Staging (Mandatory Triad)

  1. Contrast-Enhanced Multiphase CT (Chest/Abdomen/Pelvis) OR MRI Liver/Pelvis: Anatomical detail, vascular invasion, resectability assessment.
  2. Ga-68 DOTATATE PET-CT: Functional staging, SSTR status, unknown primary detection, bone mets. Standard of care where available.
  3. Echocardiogram (TTE): Baseline screen for Carcinoid Heart Disease (TR, PS, RV dilation) if Syndrome present or 5-HIAA elevated. Repeat surveillance 6-12 monthly.

4. Pathology Confirmation

  • Core Needle Biopsy preferred over FNA for grading (Ki-67 assessment requires tissue architecture/cellularity).
  • Ki-67 Index: Must be reported per WHO 2019 guidelines (hot spot counting, % positive nuclei).
  • SSTR2A IHC: Recommended for all new diagnoses (predicts SSA/PRRT response).

Management Principles: Multidisciplinary Team (MDT) Approach

All GI-NETs should be discussed in a Specialist NET MDT (Surgeon, Medical Oncologist, Nuclear Medicine, Radiologist, Pathologist, Endocrinologist, Specialist Nurse).

1. Surgery: The Only Curative Modality

  • Curative Intent (Localized/Regional):
  • Small Bowel: Segmental resection + wide mesenteric lymphadenectomy (preserve vascular arcade if possible). Address fibrosis.
  • Rectal:
  • <1 cm, G1, submucosal only → Endoscopic Resection (EMR/ESD) or Transanal Excision (TAE/TAMIS).
  • >1 cm, G2, muscularis propria invasion, LVI+ → TME (Total Mesorectal Excision) ± Neoadjuvant therapy (rare).
  • Gastric Type 1: Endoscopic mucosal resection (EMR/ESD) for lesions >1 cm or multiple. Surveillance for <1 cm.
  • Gastric Type 3 / Colon / Appendix (GCA/High risk): Formal oncologic resection (Gastrectomy / Right Hemicolectomy / Segmental colectomy) + Lymphadenectomy.
  • Cytoreductive / Debulking Surgery (Metastatic):
  • Liver Metastases: Resection/ablation if >90% tumour burden removable, preserved liver function, low grade (G1/G2), stable disease. Improves symptom control and survival.
  • Primary Tumour Resection in Stage IV: Palliative resection of primary (e.g., ileal NET) recommended even with unresectable liver mets to prevent future obstruction/ischaemia/bleeding (high lifetime risk ~30-50%).

2. Somatostatin Analogues (SSAs) – Backbone of Systemic Therapy

  • Agents: Octreotide LAR (30 mg q28d), Lanreotide Autogel (120 mg q28d).
  • Indications:
  1. Symptom Control (Carcinoid Syndrome): First line. Controls flushing/diarrhoea in ~70%.
  2. Antiproliferative (PFS Benefit): PROMID (Midgut) and CLARINET (G1/G2 GEP-NETs) trials proved significant PFS prolongation. Standard for unresectable/metastatic G1/G2 (Ki-67 <10% ideally).
  • Dosing: Titrate to symptom control (short-acting SC rescue doses initially). Consider q21d or dose escalation (Octreotide 40-60mg) for breakthrough.
  • Side Effects: GI (steatorrhoea, gallstones, biliary sludge), Injection site pain, Hyperglycaemia, Bradycardia.

3. Telotristat Ethyl (Xermelo®)

  • Mechanism: Tryptophan Hydroxylase (TPH) inhibitor → reduces serotonin synthesis peripherally.
  • Indication: Refractory Carcinoid Syndrome Diarrhoea despite maximal SSA therapy (≥4 bowel movements/day).
  • Dose: 250 mg TDS with food. Reduces 5-HIAA and stool frequency. Monitor liver enzymes, depression.

4. Peptide Receptor Radionuclide Therapy (PRRT) – Lu-177 DOTATATE

  • Mechanism: Beta-emitter (Lu-177) linked to Somatostatin analogue → targeted internal radiation to SSTR2+ tumour cells.
  • Landmark Trial: NETTER-1 (Progressive Midgut G1/G2 NETs) → PFS benefit 79% vs High-dose Octreotide.
  • Indications (EMA/FDA): SSTR-positive, progressive, well-differentiated (G1/G2) GEP-NETs.
  • Selection: Ga-68 DOTATATE PET positive (Krenning Score 3-4), adequate renal function (GFR >40-50), bone marrow reserve.
  • Protocol: 4 cycles x 7.4 GBq q8-12 weeks + Amino acid infusion (renal protection).
  • Toxicity: Nausea, fatigue, transient cytopenias, Renal toxicity (late), Secondary MDS/AML (rare, ~2-3%).

5. Molecular Targeted Therapy

  • Everolimus (mTOR Inhibitor):
  • RADIANT-4: PFS benefit in Progressive, Non-functional Lung/GI NETs (G1/G2).
  • Indication: Progressive NET G1/G2 (Lung/GI) after SSA failure or unsuitable for PRRT. Pancreatic NETs also.
  • SE: Stomatitis, infections, hyperglycaemia, pneumonitis, proteinuria.
  • Sunitinib (Tyrosine Kinase Inhibitor): Approved for Pancreatic NET (pNET) only. Not standard for GI-NETs.

6. Chemotherapy

  • Well-Differentiated NET G1/G2: Low efficacy (Response rates <10%). Generally avoided unless rapid progression/visceral crisis.
  • Well-Differentiated NET G3 (Ki-67 20-55%): TEM/CAP (Temozolomide + Capecitabine) is emerging preferred regimen (ORR ~30-40%, better tolerated than Platinum). Platinum/Etoposide less effective than in NEC.
  • Poorly Differentiated NEC G3: Cisplatin/Carboplatin + Etoposide is standard 1st line (ORR 40-60%). High response but short duration. Maintenance therapy debated.

7. Liver-Directed Therapies (for Liver-Dominant Mets)

  • Transarterial Embolization (TAE) / Chemoembolization (TACE) / Radioembolization (TARE/SIRT – Y-90): Symptom control, downstaging, bridge to transplant/resection. TARE preferred for functional tumours (lower risk of carcinoid crisis post-embolization syndrome vs TACE).
  • Thermal Ablation (RFA/MWA): Oligometastatic disease (<3-4 lesions, <3-4 cm).

8. Management of Carcinoid Heart Disease (CHD)

  • Medical: Strict SSA control (lowers 5-HIAA). Diuretics for RV failure.
  • Surgical: Tricuspid Valve Replacement (TVR) ± Pulmonary Valve Replacement (PVR). Mechanical vs Bioprosthetic (anticoagulation challenges in NET patients). Timing: Before severe RV dysfunction. Peri-op Octreotide infusion mandatory.

Follow-Up & Surveillance Strategy

Surveillance is risk-adapted based on Grade, Stage, Resection Margin (R0/R1), and Ki-67.

Risk Category Typical Profile Surveillance Schedule (Years 1-3 / 4-5 / 5-10)
Very Low Appendix <1cm G1, Rectal <1cm G1 (R0 endoscopic), Gastric Type 1 <1cm Colonoscopy at 1 yr (rectal/appendiceal). Gastric: Gastroscopy 6-12 mo. No routine CT/PET if R0.
Low SI-NET G1 R0, Gastric Type 2 R0, Rectal 1-2cm G1 R0 CT/MRI + CgA + 5-HIAA q6-12mo x 3-5yr, then annually. Echo if Syndrome hx.
Intermediate SI-NET G2, R1 resection, Node+, Gastric Type 3 R0, Colon NET CT/MRI + CgA + 5-HIAA q3-6mo x 3yr, q6-12mo x 2yr, then annually. Ga-68 PET at 12mo baseline.
High NET G3, NEC, R2 resection, High Ki-67 (>20%), Multiple Liver Mets CT/MRI + Markers q3-4mo x 2-3yr. Ga-68 PET / FDG PET per clinical need. Clinical trial enrolment priority.

Lifelong surveillance is recommended for most resected GI-NETs due to risk of late recurrence (up to 10-15+ years).

Prognosis and Survival Outcomes

Prognosis is highly heterogeneous. Stage and Grade are the dominant drivers.

  • Localized (Stage I/II), R0 Resection: 5-year OS >90-95% (G1/G2).
  • Regional (Stage III), N+: 5-year OS 65-85% (G1/G2). Adjuvant therapy not standard (no proven OS benefit for SSA/Everolimus adjuvant).
  • Metastatic (Stage IV):
  • G1 (Ki-67 <3%): Median OS >10-15 years (indolent).
  • G2 (Ki-67 3-20%): Median OS 5-10 years.
  • NET G3 (Ki-67 20-55%): Median OS 2-5 years.
  • NEC G3: Median OS 12-18 months (with chemo).
  • Prognostic Nomograms: Available (e.g., ENETS, MSKCC) incorporating Grade, Stage, Age, Site, CgA, LDH, Alkaline Phosphatase.

Living with GI-NETs: Quality of Life & Supportive Care

Nutritional Management

  • Carcinoid Syndrome Diarrhoea: Low amine diet (avoid aged cheese, cured meats, fermented foods, alcohol). Soluble fibre (oats, banana, psyllium). Pancreatic enzyme replacement (PERT) if steatorrhoea (SSA-induced exocrine insufficiency).
  • Niacin Supplementation: Nicotinamide 50-100 mg/day (non-flushing form) for all patients with elevated 5-HIAA or Carcinoid Syndrome to prevent Pellagra.
  • Bone Health: SSAs + Somatostatin → reduced Vitamin D absorption + potential bone density loss. Monitor DEXA, supplement Vit D/Calcium.

Psychological Support

  • Chronic “cancer as a chronic disease” burden. Uncertainty of surveillance scans (“scanxiety”).
  • Access to NET Specialist Nurses, Patient Advocacy Groups (e.g., NET Patient Foundation, Carcinoid Cancer Foundation, Neuroendocrine Cancer UK).

Fertility & Pregnancy

  • SSAs generally considered safe in pregnancy (limited data, but used for acromegaly).
  • PRRT / Chemo / Everolimus Contraindicated.
  • Surgery ideally deferred to 2nd trimester if urgent.

Emerging Therapies & Future Directions

  1. Novel PRRT Radioligands: Ac-225 DOTATATE (Alpha-emitter) – higher linear energy transfer, overcoming beta-resistance. Early phase trials show impressive responses in PRRT-refractory disease.
  2. SSTR Antagonists (e.g., JR11 / Lu-177-OPS201): Antagonists bind more receptor sites (internalization not required) → higher tumour dose, lower kidney dose. Phase III trials ongoing (COMPETE, etc.).
  3. Immunotherapy: Immune Checkpoint Inhibitors (ICI) – Low efficacy in well-differentiated NETs (cold tumours). High efficacy in subset of NEC with high TMB/MSI-H/dMMR. Pembrolizumab approved for MSI-H/dMMR solid tumours.
  4. Targeted Agents: Surufatinib (VEGFR/FGFR/CSF1R inhibitor) – Approved in China for extrapancreatic NETs (SANET-ep trial). Belzutifan (HIF-2α inhibitor) – Trials in VHL-associated and sporadic NETs.
  5. Circulating Tumour DNA (ctDNA) / Liquid Biopsy: Monitoring minimal residual disease (MRD) and early recurrence detection. MEN1, DAXX, ATRX, MUT mutations detectable.
  6. Theranostics Expansion: FAPI PET (Fibroblast Activation Protein) – Targets cancer-associated fibroblasts (stromal target). High uptake in NETs (including SSTR-negative). Lu-177/FAPI therapeutic trials underway.

Frequently Asked Questions (FAQ)

Q: Is a “carcinoid tumour” cancer?

A: Yes. The term “carcinoid” implies “carcinoma-like,” but all GI-NETs have malignant potential. The modern term Neuroendocrine Tumour (NET) emphasizes they are a distinct cancer type with a spectrum of behaviour from indolent to aggressive.

Q: Can I take Proton Pump Inhibitors (PPIs) if I have a Gastric NET?

A: Type 1 Gastric NETs: PPIs cause the hypergastrinaemia driving the tumour. However, stopping PPIs abruptly causes rebound hypersecretion. Management is complex: usually, we continue PPI or switch to H2-blocker after endoscopic resection/surveillance plan is set, or perform antrectomy to remove the G-cell drive. Do not stop PPIs without specialist advice.

Type 3 Gastric NETs: PPIs not causative. Can be used for symptom control.

Q: Does surgery cure metastatic disease?

A: Surgery is rarely curative in Stage IV, but cytoreductive surgery (debulking >90%) significantly prolongs survival and controls hormonal symptoms. Resection of the primary tumour in asymptomatic Stage IV midgut NETs prevents future surgical emergencies (obstruction/ischaemia).

Q: What is the “Carcinoid Crisis” and how dangerous is it?

A: It is a life-threatening hemodynamic collapse (severe hypotension/hypertension, bronchospasm, flushing) triggered by stress/anaesthesia. Mortality is high without prophylaxis. Mandatory IV Octreotide cover for any surgery, endoscopy, biopsy, or embolization in patients with known syndrome or elevated 5-HIAA.

Q: Are my children at risk?

A: Most GI-NETs are sporadic. However, if you have multiple tumours, young onset (<40), family history of endocrine tumours, or specific histology (e.g., SDH-deficient gastric NET), germline genetic testing is recommended. If a mutation is found, cascade testing for relatives is offered.

Q: Can I have an MRI with contrast if I have a NET?

A: Yes. Gadolinium-based contrast agents are safe. Ga-68 DOTATATE PET-CT involves radiation (approx. 4-5 mSv effective dose), similar to a diagnostic CT.

References

  1. Boudreaux, J.P., Klimstra, D.S., Hassan, M.M., Wolin, E.M., O’Dorisio, T.M., Goldsmith, S.J., Strosberg, J.R., et al. (2021) ‘The NANETS Consensus Guidelines for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum’, Pancreas, 50(5), pp. 599–613.
  2. Pavel, M., Öberg, K., Falconi, M., Krenning, E.P., Sundin, A., Perren, A., Berruti, A., et al. (2020) ‘ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms and of Neuroendocrine Neoplasms of Unknown Primary Site’, Neuroendocrinology, 110(4), pp. 365–388.
  3. Rindi, G., Klimstra, D.S., Abedi-Ardekani, B., Asa, S.L., Bosman, F.T., Brambilla, E., Busam, K.J., et al. (2022) ‘The 2022 WHO Classification of Neuroendocrine Neoplasms: An Overview’, Neuroendocrinology, 112(5), pp. 355–373.
  4. Strosberg, J.R., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., et al. (2017) ‘Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors’, New England Journal of Medicine, 376(2), pp. 125–135. (NETTER-1 Trial).
  5. Kulke, M.H., Anthony, L.B., Bushnell, D.L., de Herder, W.W., Goldsmith, S.J., Klimstra, D.S., Kvols, L.K., et al. (2017) ‘NANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas’, Pancreas, 46(6), pp. 707–714.
  6. Cives, M. and Strosberg, J. (2019) ‘Telotristat Ethyl for the Treatment of Carcinoid Syndrome Diarrhea’, Therapeutic Advances in Gastroenterology, 12, p. 1756284819840456.
  7. Modlin, I.M., Lye, K.D., Kidd, M. (2003) ‘A 5-decade analysis of 13,715 carcinoid tumors’, Cancer, 97(4), pp. 934–959. (Classic epidemiological reference).
  8. Pape, U.F., Jann, H., Müller-Nordhorn, J., Bockelbrink, A., Berndt, U., Willich, S.N., Wiedenmann, B. (2008) ‘Prognostic Factors of Long-Term Outcome in Gastroenteropancreatic Neuroendocrine Tumours’, Endocrine-Related Cancer, 15(3), pp. 683–690.
  9. Kianmanesh, R., Gronbaek, H., Perren, A., Taal, B., Berruti, A., Bouché, O., Cadiot, G., et al. (2016) ‘ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms of the Appendix and the Carcinoid Syndrome’, Neuroendocrinology, 103(2), pp. 147–174.
  10. Sundin, A., Garske-Roman, U., Granberg, D., Öberg, K. (2017) ‘Differences in outcome for patients with gastroenteropancreatic neuroendocrine tumours treated with 177Lu-DOTATATE: A retrospective analysis of the Swedish National Registry’, European Journal of Nuclear Medicine and Molecular Imaging, 44(9), pp. 1469–1478.
  11. Yao, J.C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., et al. (2016) ‘Everolimus for the Treatment of Advanced, Non-Functional Neuroendocrine Tumours of the Lung or Gastrointestinal Tract (RADIANT-4): A Randomised, Placebo-Controlled, Phase 3 Study’, The Lancet, 387(10022), pp. 968–977.
  12. National Comprehensive Cancer Network (NCCN) (2024) Neuroendocrine and Adrenal Tumors, Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (Accessed: 20 May 2024).
  13. National Institute for Health and Care Excellence (NICE) (2023) Lutetium-177-DOTATATE for Treating Unresectable or Metastatic Neuroendocrine Tumours, Technology Appraisal Guidance [TA599]. London: NICE.
  14. Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D.K., Capdevila, J., Caplin, M., Kos-Kudla, B., et al. (2016) ‘ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors’, Neuroendocrinology, 103(2), pp. 153–171.
  15. Ramage, J.K., Ahmed, A., Ardill, J., Bax, N., Breen, D.J., Caplin, M.E., Corrie, P., et al. (2012) ‘Guidelines for the Management of Gastroenteropancreatic Neuroendocrine (Including Carcinoid) Tumours’, Gut, 61(1), pp. 6–32. (UKINETS Guidelines – foundational).

Disclaimer